Form 4: Ocugen Director Uday Kompella Granted Significant Stock Options

Ocugen, Inc. Director Uday Kompella was granted 151,316 stock options with an exercise price of $0.95, vesting upon the earlier of June 5, 2026, or the next annual meeting.

Summary

• Uday Kompella, a Director at Ocugen, Inc. (OCGN), acquired 151,316 derivative securities in the form of stock options.
• The transaction date for this grant was June 5, 2025.
• Each option has an exercise price of $0.95.
• The options are set to expire on June 5, 2035.
• The options will vest upon the earlier of June 5, 2026, or Ocugen, Inc.'s next annual meeting of stockholders, contingent on Mr. Kompella's continued service.
• Following this transaction, Mr. Kompella beneficially owns 151,316 derivative securities (options).

Sentiment

Score: 6

Explanation: Slightly positive, as it represents a standard compensation practice that aligns director interests with shareholders, without indicating any immediate negative operational or financial news.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, as the options gain value if the company's stock price increases.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The grant of these options, with a vesting schedule tied to continued service, indicates an expectation of the director's ongoing involvement and contribution to the company's future performance.

Industry Context

This Form 4 filing represents a routine insider transaction, specifically the grant of equity compensation to a director, which is a common practice across industries to incentivize and retain key personnel and align their interests with shareholders.

Related Party Transactions

• The grant of stock options to Uday Kompella, a director of Ocugen, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant of options can be seen as a positive for aligning management incentives with shareholder value creation. However, if exercised, these options could lead to minor dilution of existing shares.

Next Steps

• The options will vest upon the earlier of June 5, 2026, or Ocugen, Inc.'s next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Ocugen, OCGN, Form 4, Stock Options, Director Compensation, Insider Transaction, Equity Grant, Derivative Securities